Li Lab: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
(184 intermediate revisions by 2 users not shown)
Line 6: Line 6:
<div style="float:left;margin-left:0.3em;margin-right:0.7em">
<div style="float:left;margin-left:0.3em;margin-right:0.7em">


== '''Welcome to Wei Li's Computational Genomics Lab''' ==  
== '''Computational Cancer Epigenomics and Transcriptomics (PI: Wei Li)''' ==  


[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
Line 15: Line 15:


==Recent News==
==Recent News==
. 03/2011: Liguo's Prostate Cancer RNA-seq paper has been tentatively accepted to  '''PNAS'''.
. 08/2015: Kaifu's Cancer Big-data analysis paper is published in '''Nature Genetics'''. This work links broad H3K4me3 to pan-cancer tumor suppressors. See Nature Editor’s [http://blogs.nature.com/freeassociation/2015/08/methylation-marks-tumor-suppressors.html Blog] and Chinese Report in [http://www.ebiotrade.com/newsf/2015-8/2015825165005119.htm ebiotrade.com]


. 01/2011Yuanxin's fragile nucleosome paper has been accepted to  '''Genome Research'''.
. 07/2015Wei will become a regular member of the '''NIH GCAT''' (Genomics, Computational Biology and Technology) study section.


. 01/2011: Yuanxin and Liguo's  Atoh1 targetome paper has been accepted to  '''PNAS'''.
. 06/2015: Kaifu will start his '''tenure-track faculty''' position at Cornell University & Methodist Hospital. Congratulations!


. 12/2010: Liguo's fly RNA-seq paper has been published in  '''Genome Research'''.
. 06/2015: We will receive a '''NEW NIH/NCI R01''' grant (scored at 5%ile) to study 3`UTR alternations in human cancers.


. 10/2010A Texas '''CPRIT grant''' has been funded. We will work with Dr. Goodell at BCM to understand DNA Methylgransferase 3B in normal and malignant hematopoiesis.  
. 03/2015Kaifu's MeCP2 mCH binding paper (w/ Zoghbi lab) is accepted to '''PNAS'''.


. 08/2010: Our '''Pilot Project''' has been funded by a NIH Stem Cell P01 Grant.  
. 3/2015: We received a NEW '''CPRIT''' grant.


. 07/2010The DNA methylation platform comparision paper has been accepted to '''Nature Biotechnology'''.
. 01/2015Deqiang, HJ and Ben's HSC novel noncoding RNA paper is accepted to '''Cell Stem Cell''' -- the 100th paper we published.


. 06/2010: Hao Zhao will join us as a '''postdoc fellow'''. Hao has a PhD in Computer Science from City University of Hong Kong. Welcome!
. 12/2014: Zheng Xia is awarded a '''Keck fellowship''' in Computational Cancer Biology.


. 05/2010Our paper titled "Histone modifications and chromatin organization in prostate cancer" has been accepted by '''Epigenomics'''.
. 11/2014Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in '''Nature Communications'''.


. 01/2010A Texas '''CPRIT grant''' has been funded. We will use ChIP-seq and RNA-seq to analyze Androgen Receptor (AR) function in Prostate Cancer with Dr. Weigel at BCM.
. 09/2014Liguo's ChIP-exo methodology paper (MACE) is accepted to '''Nucleic Acids Research'''.  MACE is recommended by Active Motif as the software solution for the company's new [https://www.activemotif.com/catalog/1050/chip-exo ChIP-exo kit and service].


. 01/2010: A '''CPRIT multi-investigator planning award''' has been funded. This project will bring together a "dream team" in epigenetics researchWe will direct the bioinformatics component for LONESTAR.
. 09/2014: Deqiang will start his '''tenure-track assistant professor''' position. Job well done.   


. 01/2010Wei Li is an invited speaker in the American Association for Cancer Research (AACR) Special '''Conference on Cancer Epigenetics''' at Puerto Rico.
. 09/2014Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to '''Molecular Cancer Research '''.  


. 09/2014:  Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to '''Cell'''.


. 08/2014:  '''Three Collaborative CPRIT grants''' are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.


. 06/2014:  Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to '''Cell Stem Cell '''.
. 06/2014:  Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to '''Molecular Cell '''.
. 02/2014:  Zheng's brain tumor 3'UTR regulator paper is accepted to '''Nature'''. This paper was initially rejected after review twice. We appealed twice with success and finally made it in the 3rd submission.
. 02/2014:  Welcome our new postdoc Jianzhong Su and graduate student Xueqiu Lin.
. 02/2014:  Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to '''Cell Stem Cell'''.
. 01/2014:  Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to '''Genome Biology'''.
. 01/2014:  Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to '''Nature'''. This work links transcription elongation to tumor suppression.
[[Image:Banner.jpg‎‎]]


[http://openwetware.org/wiki/Li_Lab:news News Archive]
[http://openwetware.org/wiki/Li_Lab:news News Archive]
Line 46: Line 65:
{|width="*"
{|width="*"
|
|
{| style="width: 100%;  text-align:center;font-size:12px;font-variant: small-caps;width: 18px; " align="center"  
{| style="width: 728px;  text-align:center;font-size:12px;font-variant: small-caps;width: 18px; " align="center"  
|-
|-


Line 62: Line 81:
<div style="border-bottom: 1px dashed #9999CC;">
<div style="border-bottom: 1px dashed #9999CC;">


== '''A Genomic View of Epigenetic and Transcriptional Regulation''' ==
Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have
* '''Published''' more than 75 peer-reviewed papers through solid methodology development and extensive collaboration research, including 28 in '''Nature, Science and Cell''' series.
 
* '''Been well-funded''' by NIH and Texas CPRIT with total external funding >$1.3 million per year. Dr Li is the PI on the following 4 major grants: NIH R01HG007538 (2013-2018) and R01CA193466 (2015-); CPRIT RP110471-C3 (2011-2016) and RP150292 (2015-2018).
* '''Mentored''' the first 3 postdoc trainees to start their tenure track faculty positions in prestigious research institutions in the US.
 
We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1900 citations since 2008.
 
In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.


* '''Chromatin Factors''': ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..


Our lab is focused on the design and application of bioinformatics algorithms to elucidate global regulatory mechanism by integrating data from ChIP-seq, DNA methylation, Nucleosome positioning, and RNA-seq.  We are also working with bench and clinical collaborators to understand epigenetic gene regulation and transcription dynamics in various biological processes and disease models.  
* '''DNA Methylation''': DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.  


We have developed a number of widely used algorithms to detect and annotate genome-wide cis-regulatory regions, including a Hidden Markov Model (Bioinformatics 2005) and MAT (PNAS 2006) for analyzing ChIP-chip experiments on genome tiling arrays, CEAS (NAR 2006) for cis-regulatory element annotation, xMAN (BMC Genomics 2008) for microarray probe mapping, MACS (Genome Biology 2008) for model based analysis of ChIP-seq, BSMAP (BMC Bioinformatics 2009) for DNA methylation analysis using Bisulfite-seq, and MMES (PLoS ONE 2010) for alternative splicing using RNA-seq. These algorithms have gathered thousands of academic users worldwide and hundreds of citations, including > 30 papers in Cell and Nature serious. We are currently working on bioinformatics development for 1) Transcription factor binding and histone modifications (ChIP-seq); 2) DNA methylation at single nucleotide resolution (Bisulfite-seq); 3) Nucleosome remodeling (Mnase-seq); 4) Alternative splicing (RNA-seq).
* '''Nucleosome Organization''': Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.


We have extensive experience in collaborative research, such as Estrogen Receptor (ER) in breast cancer (Cell 2005; Nature Genetics 2006), Androgen Receptor (AR) in prostate cancer (Molecular Cell 2007; Cell 2009) and ER/AR’s collaborating factor FoxA1 (Cell 2008). My laboratory also plays an important role in the BCM Epigenomics Data Analysis and Coordination Center for a five-year NIH Roadmap Epigenomics Program.  
* '''Transcriptome''': chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


[http://sites.google.com/a/bcm.edu/lilab/ Lab Intranet]
[http://sites.google.com/a/bcm.edu/lilab/ Lab Intranet]
[http://openwetware.org/wiki/Li_Lab openwetware]
[http://openwetware.org/wiki/Li_Lab openwetware]

Revision as of 08:23, 26 August 2015

Home        People        Publications        Collaborations        Software        Positions        Contact       


Recent News

. 08/2015: Kaifu's Cancer Big-data analysis paper is published in Nature Genetics. This work links broad H3K4me3 to pan-cancer tumor suppressors. See Nature Editor’s Blog and Chinese Report in ebiotrade.com

. 07/2015: Wei will become a regular member of the NIH GCAT (Genomics, Computational Biology and Technology) study section.

. 06/2015: Kaifu will start his tenure-track faculty position at Cornell University & Methodist Hospital. Congratulations!

. 06/2015: We will receive a NEW NIH/NCI R01 grant (scored at 5%ile) to study 3`UTR alternations in human cancers.

. 03/2015: Kaifu's MeCP2 mCH binding paper (w/ Zoghbi lab) is accepted to PNAS.

. 3/2015: We received a NEW CPRIT grant.

. 01/2015: Deqiang, HJ and Ben's HSC novel noncoding RNA paper is accepted to Cell Stem Cell -- the 100th paper we published.

. 12/2014: Zheng Xia is awarded a Keck fellowship in Computational Cancer Biology.

. 11/2014: Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in Nature Communications.

. 09/2014: Liguo's ChIP-exo methodology paper (MACE) is accepted to Nucleic Acids Research. MACE is recommended by Active Motif as the software solution for the company's new ChIP-exo kit and service.

. 09/2014: Deqiang will start his tenure-track assistant professor position. Job well done.

. 09/2014: Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to Molecular Cancer Research .

. 09/2014: Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to Cell.

. 08/2014: Three Collaborative CPRIT grants are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.

. 06/2014: Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to Cell Stem Cell .

. 06/2014: Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to Molecular Cell .

. 02/2014: Zheng's brain tumor 3'UTR regulator paper is accepted to Nature. This paper was initially rejected after review twice. We appealed twice with success and finally made it in the 3rd submission.

. 02/2014: Welcome our new postdoc Jianzhong Su and graduate student Xueqiu Lin.

. 02/2014: Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to Cell Stem Cell.

. 01/2014: Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to Genome Biology.

. 01/2014: Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to Nature. This work links transcription elongation to tumor suppression.


News Archive




Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have

  • Published more than 75 peer-reviewed papers through solid methodology development and extensive collaboration research, including 28 in Nature, Science and Cell series.
  • Been well-funded by NIH and Texas CPRIT with total external funding >$1.3 million per year. Dr Li is the PI on the following 4 major grants: NIH R01HG007538 (2013-2018) and R01CA193466 (2015-); CPRIT RP110471-C3 (2011-2016) and RP150292 (2015-2018).
  • Mentored the first 3 postdoc trainees to start their tenure track faculty positions in prestigious research institutions in the US.

We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1900 citations since 2008.

In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.

  • Chromatin Factors: ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..
  • DNA Methylation: DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.
  • Nucleosome Organization: Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.
  • Transcriptome: chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


Lab Intranet openwetware


<html> <script type="text/javascript">

 var _gaq = _gaq || [];
 _gaq.push(['_setAccount', 'UA-5924762-2']);
 _gaq.push(['_trackPageview']);
 (function() {
   var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
   ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
   var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
 })();

</script> </html>